Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCG101 in HBV-Related Hepatocellular Carcinoma
NCT05417932Phase 2Recruiting
- Sponsor
- SCG Cell Therapy
- Start
- Oct 2022
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of SCG101 in hepatocellular carcinoma (HCC), sponsored by SCG Cell Therapy. Primary endpoints: Safety and tolerability of SCG101 at 100 days and Tumor response of SCG101 up to 15 years. Started Oct 2022; status: recruiting.
02
Drugs
SCG101
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05417932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417932.